Function and Mechanism of TET Regulation of Tumor Immunity

TET调节肿瘤免疫的功能及机制

基本信息

项目摘要

Project Abstract Nearly half of newly discovered cancer driver genes discovered by the cancer genomic studies encode proteins involved in histone or DNA modification, including the TET family of DNA dioxygenases. Loss-of-function mutations in TET genes occur early and frequently in human hematopoietic malignancy. Mutations in TET genes, however, are uncommon in solid tumors. Instead, TET activity is significantly reduced in different types of human tumors. We do not know the significance of decreased TET activity in solid tumors. In this study, we hypothesize that TET has a previously unrecognized key function in both the JAK-STAT and NF-κ pathways. Inactivation of TET in results in chronic tumor-promoting inflammation and escape from anti-tumor immunity. Thus, stimulating TET activity represents a viable opportunity to enhance antitumor immunity and to improve immunotherapy. We will test this hypothesis by defining the following aspects of TET2 activity: The function and mechanism of TET2 in the JAK-STAT pathway and in tumor immunity (Aim 1); The regulation of TET2 and tumor immunity by reversible monoubiquitylation (Aim 2); and The catalytically independent function and mechanism of TET2 in tumor suppression (Aim 3). During the past funding period, we have made the following discoveries that significantly affect the TET field and that form the foundation for this investigation: (1) Multiple oncometabolites produced or accumulated by mutations in different metabolic enzymes act as antagonists α-ketoglutarate (αKG) and inhibit multiple αKG- dependent enzymes, including TET enzymes. (2) TET activity is dynamically regulated in vivo. (3) Development of solid tumors of many different types is associated with a substantial decrease in TET activity. (4) TET is reversibly monoubiquitylated by CRL4VprBP E3 ligase and UPS15 deubiquitylase, enhancing and impairing TET activity, respectively. This regulation is disrupted by multiple recurrent tumor-derived mutations in TET2. (5) HIV protein Vpr reprograms CRL4VprBP E3 ligase to catalyze polyubiquitylation and degradation of TET proteins to sustain the expression of pro-inflammatory cytokine and promote HIV pathogenesis. (6) Multiple sequence- specific transcription factors (TFs) recruit TET2 to their target genes, including members of NF-κB and STAT families. (7) Loss of TET2 function in tumors impairs interferon signaling, chemokine production, and T cell infiltration, and confers resistance to tumor immunity and immunotherapy. This investigation is built on our pioneering and extensive study of the then newly discovered TET enzymes. It will investigate a novel aspect of cytokine signaling and tumor immunity regulation—by TET- mediated DNA demethylation. It will use newly developed technology and mouse strains to determine how TET proteins regulate gene expression by catalytically-dependent and -independent mechanisms. It will explore a novel regulation of TET by reversible monoubiquitylation and the therapeutic opportunity of this regulation. This investigation represents the first exploration on the function and mechanism of TET in tumor immunity.
项目摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALBERT Sidney BALDWIN其他文献

ALBERT Sidney BALDWIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALBERT Sidney BALDWIN', 18)}}的其他基金

SToP Cancer SPORE: Developmental Research Program
STOP Cancer SPORE:发展研究计划
  • 批准号:
    10705611
  • 财政年份:
    2022
  • 资助金额:
    $ 31.94万
  • 项目类别:
SToP Cancer SPORE: Developmental Research Program
STOP Cancer SPORE:发展研究计划
  • 批准号:
    10334088
  • 财政年份:
    2022
  • 资助金额:
    $ 31.94万
  • 项目类别:
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
一个联盟致力于通过离体器官平台转化神经系统疾病的疗法
  • 批准号:
    10436954
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
一个联盟致力于通过离体器官平台转化神经系统疾病的疗法
  • 批准号:
    10214893
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
一个联盟致力于通过离体器官平台转化神经系统疾病的疗法
  • 批准号:
    10655357
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells
癌症中的 IKK/NF-kappaB 信号传导:治疗、耐药性和肿瘤起始细胞
  • 批准号:
    9214322
  • 财政年份:
    2016
  • 资助金额:
    $ 31.94万
  • 项目类别:
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells
癌症中的 IKK/NF-kappaB 信号传导:治疗、耐药性和肿瘤起始细胞
  • 批准号:
    8956007
  • 财政年份:
    2016
  • 资助金额:
    $ 31.94万
  • 项目类别:
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells
癌症中的 IKK/NF-kappaB 信号传导:治疗、耐药性和肿瘤起始细胞
  • 批准号:
    10330374
  • 财政年份:
    2016
  • 资助金额:
    $ 31.94万
  • 项目类别:
Function and Mechanism of TET Regulation of Tumor Immunity
TET调节肿瘤免疫的功能及机制
  • 批准号:
    10689090
  • 财政年份:
    2012
  • 资助金额:
    $ 31.94万
  • 项目类别:
Regulation of Basal-Like and Her2+ Breast Cancer Phenotypes by IKK/NF-kappaB
IKK/NF-kappaB 对 Basal-Like 和 Her2 乳腺癌表型的调节
  • 批准号:
    8205037
  • 财政年份:
    2010
  • 资助金额:
    $ 31.94万
  • 项目类别:

相似国自然基金

帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 批准年份:
    2021
  • 资助金额:
    58.00 万元
  • 项目类别:
    面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
  • 批准号:
    31672538
  • 批准年份:
    2016
  • 资助金额:
    62.0 万元
  • 项目类别:
    面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 批准年份:
    2013
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
  • 批准号:
    81172529
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
  • 批准号:
    81070952
  • 批准年份:
    2010
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
  • 批准号:
    30672361
  • 批准年份:
    2006
  • 资助金额:
    24.0 万元
  • 项目类别:
    面上项目

相似海外基金

Chromatin-binding deubiquitinase MYSM1 as a putative drug target for cMYC-driven B cell lymphoma
染色质结合去泛素酶 MYSM1 作为 cMYC 驱动的 B 细胞淋巴瘤的推定药物靶点
  • 批准号:
    478278
  • 财政年份:
    2023
  • 资助金额:
    $ 31.94万
  • 项目类别:
    Operating Grants
The role of chromatin structure in Alternative Lengthening of Telomeres (ALT): lessons from the Heterochromatin Protein 1 Binding Partner 3 (HP1BP3).
染色质结构在端粒选择性延长 (ALT) 中的作用:异染色质蛋白 1 结合伴侣 3 (HP1BP3) 的经验教训。
  • 批准号:
    MR/X018709/1
  • 财政年份:
    2023
  • 资助金额:
    $ 31.94万
  • 项目类别:
    Research Grant
Chromatin Regulator KAT6B and its Role in gene expression and DNA binding
染色质调节因子 KAT6B 及其在基因表达和 DNA 结合中的作用
  • 批准号:
    2886693
  • 财政年份:
    2023
  • 资助金额:
    $ 31.94万
  • 项目类别:
    Studentship
Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding
照亮“暗”激酶 - 对蛋白质组易位和染色质结合的影响
  • 批准号:
    10480189
  • 财政年份:
    2022
  • 资助金额:
    $ 31.94万
  • 项目类别:
A low-input compatible, end-to-end kitted HiChIP workflow for concurrent analyses of transcriptional protein binding and chromatin interactions toward a mechanistic understanding of gene regulation
低输入兼容、端到端配套的 HiChIP 工作流程,用于同时分析转录蛋白结合和染色质相互作用,从而从原理上理解基因调控
  • 批准号:
    10383712
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
A scalable kit-based assay for multi-omic analyses of transcriptional protein binding and chromatin interactions from ultra-low input frozen and FFPE samples at single-cell resolution
基于试剂盒的可扩展测定,用于以单细胞分辨率对超低输入冷冻和 FFPE 样品中的转录蛋白结合和染色质相互作用进行多组学分析
  • 批准号:
    10277371
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
Inducing transcriptional reprogramming of leukemic B-cells by facilitating transcription factors binding to nascent decondensed chromatin
通过促进转录因子与新生脱浓缩染色质结合来诱导白血病 B 细胞的转录重编程
  • 批准号:
    10408669
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
NSF Postdoctoral Fellowship in Biology FY 2021: Analyzing the interplay of chromatin accessibility and transcription factor binding to decipher the cis-regulatory code
2021 财年 NSF 生物学博士后奖学金:分析染色质可及性和转录因子结合的相互作用以破译顺式调控密码
  • 批准号:
    2109441
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
    Fellowship Award
A low-input compatible, end-to-end kitted HiChIP workflow for concurrent analyses of transcriptional protein binding and chromatin interactions toward a mechanistic understanding of gene regulation
低输入兼容、端到端配套的 HiChIP 工作流程,用于同时分析转录蛋白结合和染色质相互作用,从而从原理上理解基因调控
  • 批准号:
    10259543
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
A scalable kit-based assay for multi-omic analyses of transcriptional protein binding and chromatin interactions from ultra-low input frozen and FFPE samples at single-cell resolution
基于试剂盒的可扩展测定,用于以单细胞分辨率对超低输入冷冻和 FFPE 样品中的转录蛋白结合和染色质相互作用进行多组学分析
  • 批准号:
    10487566
  • 财政年份:
    2021
  • 资助金额:
    $ 31.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了